Biotech Investing 101: What Investors Need to Know About Phase 1 Trials

Early clinical trial results can be tricky to interpret. Phase I studies are designed to assess safety and tolerability, but early signs of therapeutic potential can be difficult to ignore. Here's what to look for in Phase I and how to avoid getting carried away.

Apr 21, 2014 at 6:30PM

Clinical trials are huge milestones in drug development, and the success or failure of the whole company can hinge on the outcome of a single trial. The odds are generally against any given drug, as many more drugs fail in clinical trials than succeed. Trial results often trigger gain or loss in stock value, but other clinical trial events, such as initiation of a trial, reporting of interim data, or early termination of a trial can affect stock value. Investors should look for solid safety, tolerability, and efficacy results for phase 1 trials and avoid getting too carried away looking for early blockbuster potential.

The purpose of a phase 1 trial is generally to establish safety and tolerability of a drug, so success in phase 1 usually does not have a big effect on the value of the company's stock because passing a phase 1 safety trial is often expected and assumed by investors. The company will already have an idea of safety and tolerability from preclinical studies or very small proof-of-concept trials in human subjects, so any bad safety results are a large negative surprise.

However, there is no one-size-fits-all clinical trial plan for investigational drugs. In some ways, each drug is a reinvention of the wheel as a clinical program is designed for that particular drug and disease indication. Some diseases have no approved therapy and no precedent of previous clinical trials—that is the case for many rare and orphan diseases. Other drugs are entering a hotly competitive environment that includes both approved therapies and competing drugs in development.

Market response is typically measured
Immunomedics (NASDAQ:IMMU) recently reported results from three phase 1 trials of its cancer candidate IMMU-130 at the annual meeting of the American Association for Cancer Research in San Diego. As in many early cancer trials, the company enrolled cancer patients rather than healthy volunteers, and assessed efficacy along with safety and tolerability.

Therapy responses in the three trials in metastatic colorectal cancer included stable disease, partial responses, and in one case tumor shrinkage. In spite of the positive early efficacy results, Immunomedics' stock price jumped slightly but returned quickly to its previous level around $4 per share.

IMMU Chart

IMMU data by YCharts

Market bullish on Agios phase 1 data
By contrast, phase 1 results  sent stock in Agios Pharmaceuticals (NASDAQ:AGIO) skyrocketing from $35 to $45, and remained elevated.

AGIO Chart

AGIO data by YCharts

Those results, also for a cancer candidate in the area of hematologic malignancy, showed six of seven evaluable patients responding to therapy, with three complete remissions and two complete remissions with incomplete platelet recovery.

The drug, AG-221, is an inhibitor of a mutated form of the IDH2 protein, a potential cancer target. The study enrolled 22 patients with acute myeloid leukemia or myelodysplastic syndrome whose cancers tested positive for the mutation.

What's the difference?
The primary difference between the two examples is the strength of the efficacy results. Immunomedics's results were good, and definitely merit further study for the drug. But Agios' results, including the magic words "complete remission" are genuinely exciting, prompting a stronger investor reaction.

Another factor driving excitement over Agios' results is the presence of a genetic biomarker for the cancer. For a number of years the FDA has been encouraging researchers to submit drug applications that include strong companion biomarkers. Those biomarkers can be used for identifying patients most likely to benefit from therapy, to monitor success or failure of treatment, to track disease progression, or to serve as a surrogate endpoint marker for treatment response.

Strong efficacy in combination with a solid biomarker makes Agios' drug a significantly more interesting prospect. But just because the market is excited doesn't mean you need to get excited. There's a good chance that the market has overreacted to Agios' news and underreacted to Immunomedics's news.

Early trials are exactly that -- early, and any results, no matter how exciting, should be considered strictly provisional, until later, larger trials can confirm them. A show of efficacy in a trial of 8 patients is little more than a twinkle in the company's eye in terms of clinical maturity. Investors who pay a higher price for Agios stock on phase 1 results have that much more to lose if the drug doesn't come through in phase 2 and phase 3.

Fail early, fail fast
To evaluate success or failure of a phase 1 trial for investment purposes, use the same criteria that the companies themselves use. Big pharma's number one mantra is "Fail early, fail fast." In order to minimize the high costs of drug discovery and development, companies look early and often for reasons to fail or wash out a drug, and by the time a phase 1 trial is initiated, a drug has already passed numerous tests in preclinical studies. So the key question to ask at the end of a phase 1 trial is whether there's any justification to fail the drug at that point. If not, that's great news, and suggests it's worthwhile to stay invested in that drug for the next stage of development.

The number one reason a drug would fail in phase 1 would be poor safety results, such as a high number of adverse events or severe adverse events. Large numbers of patients washing out of the study because they can't tolerate the drug would be another cause for concern. Lastly, phase 1 studies are frequently used to evaluate pharmacokinetic and pharmacodynamic behavior of a drug. That can be critical if there's any question about the dosing method for the drug or its bioavailability in the body.

Rather than looking for early signs of blockbuster potential, investors should be primarily watching for a lack of negatives in phase 1. Drugs that show early blockbuster potential are attractive, but lead to greater risk if phase 2 or 3 studies don't pan out.

3 stocks poised to be multi-baggers
Betting on phase 1 data is one thing, but all investors know that the one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Catherine Shaffer has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers